Posted from: Thursday, January 05, 2017 - 05:36 PM - Present

Jardiance Receives Cardiovascular Indication

December 2, 2016 – The U.S. FDA approved a new indication for Jardiance® (empagliflozin), jointly marketed by Eli Lilly and Boehringer Ingelheim. Jardiance is the first diabetes drug indicated to decrease the risk of cardiovascular (CV)-related deaths for adults who have both type 2 diabetes and CV disease. Diabetes patients are more likely to have CV disease than individuals without diabetes. In the EMPA-REG OUTCOME® study, fewer patients who took Jardiance along with their usual diabetes and CV drugs died from heart attacks or strokes than patients who took standard drugs with a placebo.

Jardiance is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, a class of drugs that lowers blood sugar by blocking its absorption in the kidneys and forcing more to be eliminated in the urine. Jardiance was first FDA approved in August 2014 as combination therapy with lifestyle changes to improve glycemic control for adults who have type 2 diabetes. Recommended dosing for Jardiance is one tablet (either 10mg or 25mg) every morning.

 

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Sunday, November 19, 2017 - 07:54 PM.